Aviva’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$57M Buy
91,486
+310
+0.3% +$211K 0.08% 223
2026
Q1
$70.4M Buy
91,176
+2,537
+3% +$1.94M 0.12% 174
2025
Q4
$68.4M Buy
88,639
+4,357
+5% +$2.96M 0.12% 164
2025
Q3
$47.4M Buy
84,282
+4,397
+6% +$2.49M 0.09% 221
2025
Q2
$41.9M Buy
79,885
+4,525
+6% +$2.53M 0.09% 226
2025
Q1
$47.8M Buy
75,360
+10,220
+16% +$7.03M 0.12% 200
2024
Q4
$46.4M Buy
65,140
+6,222
+11% +$5.22M 0.12% 184
2024
Q3
$61.9M Buy
58,918
+1,548
+3% +$1.72M 0.16% 144
2024
Q2
$60.3M Buy
57,370
+10,081
+21% +$9.77M 0.17% 120
2024
Q1
$45.5M Buy
47,289
+5,921
+14% +$5.63M 0.15% 133
2023
Q4
$36.3M Sell
41,368
-3,524
-8% -$2.9M 0.13% 183
2023
Q3
$36.9M Buy
44,892
+15,207
+51% +$12M 0.16% 126
2023
Q2
$21.3M Buy
29,685
+7,517
+34% +$5.8M 0.09% 286
2023
Q1
$18.2M Sell
22,168
-14,697
-40% -$11.1M 0.08% 357
2022
Q4
$26.6M Sell
36,865
-943
-2% -$696K 0.13% 200
2022
Q3
$26M Sell
37,808
-1,319
-3% -$830K 0.15% 165
2022
Q2
$23.1M Buy
39,127
+12,402
+46% +$8.06M 0.12% 214
2022
Q1
$18.7M Sell
26,725
-4,505
-14% -$2.85M 0.09% 263
2021
Q4
$19.7M Buy
31,230
+549
+2% +$338K 0.08% 232
2021
Q3
$18.6M Sell
30,681
-1,550
-5% -$962K 0.08% 242
2021
Q2
$18M Buy
32,231
+101
+0.3% +$51.2K 0.08% 254
2021
Q1
$15.2M Buy
32,130
+287
+0.9% +$140K 0.07% 240
2020
Q4
$15.4M Buy
31,843
+697
+2% +$376K 0.08% 230
2020
Q3
$17.4M Sell
31,146
-848
-3% -$514K 0.1% 179
2020
Q2
$20M Buy
31,994
+12,988
+68% +$7.37M 0.12% 143
2020
Q1
$9.28M Sell
19,006
-466
-2% -$192K 0.07% 251
2019
Q4
$7.31M Sell
19,472
-935
-5% -$315K 0.04% 358
2019
Q3
$5.66M Sell
20,407
-9,704
-32% -$2.87M 0.04% 386
2019
Q2
$9.43M Sell
30,111
-311
-1% -$104K 0.06% 283
2019
Q1
$12.5M Buy
30,422
+386
+1% +$159K 0.08% 239
2018
Q4
$11.2M Sell
30,036
-8,362
-22% -$3.06M 0.08% 241
2018
Q3
$15.5M Sell
38,398
-1,531
-4% -$583K 0.09% 246
2018
Q2
$13.8M Sell
39,929
-368
-0.9% -$115K 0.08% 248
2018
Q1
$13.9M Sell
40,297
-3,923
-9% -$1.36M 0.08% 242
2017
Q4
$16.6M Sell
44,220
-5,626
-11% -$2.28M 0.09% 234
2017
Q3
$22.3M Sell
49,846
-90
-0.2% -$42.8K 0.12% 200
2017
Q2
$24.5M Sell
49,936
-1,120
-2% -$490K 0.14% 172
2017
Q1
$19.8M Sell
51,056
-2,247
-4% -$833K 0.11% 206
2016
Q4
$19.6M Buy
53,303
+3,303
+7% +$1.26M 0.12% 200
2016
Q3
$20.1M Buy
50,000
+545
+1% +$219K 0.13% 194
2016
Q2
$17.3M Buy
49,455
+4,646
+10% +$1.79M 0.12% 199
2016
Q1
$16.2M Buy
44,809
+1,297
+3% +$534K 0.12% 186
2015
Q4
$23.6M Sell
43,512
-112
-0.3% -$60.7K 0.18% 126
2015
Q3
$20.3M Sell
43,624
-941
-2% -$505K 0.17% 147
2015
Q2
$22.7M Buy
44,565
+2,110
+5% +$1.03M 0.16% 150
2015
Q1
$19.2M Buy
42,455
+10,881
+34% +$4.61M 0.13% 178
2014
Q4
$13M Buy
31,574
+110
+0.3% +$43.3K 0.1% 238
2014
Q3
$11.3M Buy
31,464
+30
+0.1% +$10.1K 0.09% 249
2014
Q2
$8.88M Sell
31,434
-70
-0.2% -$20.7K 0.07% 323
2014
Q1
$9.46M Buy
31,504
+1,890
+6% +$582K 0.08% 287
2013
Q4
$8.15M Buy
29,614
+1,605
+6% +$462K 0.07% 318
2013
Q3
$8.76M Buy
28,009
+7,405
+36% +$1.95M 0.08% 277
2013
Q2
$4.63M Buy
+20,604
New +$4.8M 0.05% 369

Other funds holding REGN

Aviva's REGN Position: Q2 2026 in Review

Aviva increased its Regeneron Pharmaceuticals (REGN) stake by 0.34% in Q2 2026, buying an estimated $211K and bringing the position to 91,486 shares worth $57M. The position accounts for 0.08% of the portfolio, ranked #223.

Aviva first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $70.4M in Q1 2026. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Aviva held 91,486 shares of Regeneron Pharmaceuticals worth $57M as of Q2 2026.
  • Aviva bought 310 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $211K.
  • Regeneron Pharmaceuticals made up 0.08% of Aviva's portfolio in Q2 2026, its #223 holding.
  • Aviva first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Aviva's Regeneron Pharmaceuticals position peaked at $70.4M in Q1 2026.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Aviva's 13F filing for Q2 2026, filed 13 Aug 2026.